Gapping up
In reaction to earnings/guidance:
- WOR +6% CALM +1.9%
Other news:
- FBIO +16.5% (announces receipt of notice of option exercise from AstraZeneca (AZN) to fully acquire Caelum Biosciences a company founded by Fortress Biotech)
- FOLD +12.4% (Amicus Therapeutics and ARYA Sciences Acquisition Corp IV (ARYD) announce formation of a next-generation genetic medicine company: "Caritas Therapeutics")
- DLTR +6.6% (increases share repurchase authorization to $2.5 bln)
- LCID +6.4% (customers expected to begin receiving Lucid Air Dream vehicles in late Oct 2021)
- NRXP +5.3% (announces second favorable safety report for ZYESAMI (aviptadil) in NIH sponsored ACTIV-3b critical care study in patients with life-threatening COVID-19)
- AFRM +3.6% (co says crypto holdings are a "new and coming soon" feature)
- ATRA +3.5% (presents Phase 1 study update of ATA188)
- ABG +3.1% (acquires Larry H. Miller Dealerships and Total Care Auto; adds ~$5.7 bln in annualized revenue)
- TMDX +2.7% (FDA grants premarket approval for OCS Liver System)
- AZN +2.2% (to fully acquire Caelum Biosciences)
- CBIO +2% (FDA grants Orphan Disease Designation for MarzAA)
- WVE +1.7% (announces new data for RNA editing capability and provides update on AATD program)
- IMMP +1.7% (received a €2126617 (~ A$3430952) R&D tax incentive payment in cash from the French Government )
- SLDB +1.6% (reports additional pulmonary function results from the ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001)
- DNN +1.4% (announces US$50 mln at-the-market offering program)
- OVV +1.4% (receives regulatory approvals for share buy-back program)
- TGTX +1.4% (Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab)
Analyst comments:
- SPR +2.8% (upgraded to Outperform from Mkt Perform at Bernstein)
- BA +2.5% (upgraded to Outperform from Mkt Perform at Bernstein)
- LLY +2.2% (upgraded to Buy from Neutral at Citigroup)
- NEXA +2.2% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- ARCH +1.8% (upgraded to Buy from Neutral at Citigroup)
- CW +1.8% (upgraded to Outperform from Neutral at Robert W. Baird)
- CAG +1% (upgraded to Neutral from Underperform at Credit Suisse)
- UBS +1% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)